保肝降脂方联合水飞蓟宾治疗湿浊内停型代谢相关脂肪性肝病临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R575.5

基金项目:

温州市科技局项目(Y20190720)


Clinical Study on Baogan Jiangzhi Prescription Combined with Silybin for Metabolism Fatty Liver Disease of Internal Retention of Dampness Turbidity Type
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察保肝降脂方联合水飞蓟宾治疗湿浊内停型代谢相关脂肪性肝病(MAFLD) 的临床疗效及对患者肝功能、血脂水平的影响。方法:选取140 例湿浊内停型MAFLD 患者,按随机数字表法分为对照组和观察组各70 例。对照组给予水飞蓟宾治疗,配合合理饮食、适当锻炼、控制体质量;观察组在此基础上加用保肝降脂方治疗。2 组均治疗3 个月。对比2 组治疗前后中医证候积分、肝功能指标及血脂水平,比较2 组临床疗效。结果:治疗后,2 组中医证候积分均较治疗前降低(P<0.05),观察组中医证候积分低于对照组(P<0.05)。观察组总有效率为92.86%,高于对照组的80.00% (P<0.05)。治疗后,2 组血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、谷氨酰转肽酶(GGT) 水平均较治疗前降低(P<0.05),观察组血清AST、ALT、GGT 水平均低于对照组(P<0.05)。治疗后,2 组总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C) 水平均较治疗前降低(P<0.05),高密度脂蛋白胆固醇(HDL-C) 水平较治疗前升高(P<0.05);观察组TC、TG、LDL-C 水平均低于对照组(P<0.05),HDL-C 水平高于对照组(P<0.05)。结论:保肝降脂方联合水飞蓟宾治疗湿浊内停型MAFLD,可改善患者的临床症状、肝功能及血脂水平。

    Abstract:

    Abstract:Objective:To observe the clinical effect of Baogan Jiangzhi prescription combined with silybin for metabolism fatty liver disease(MAFLD) of internal retention of dampness turbidity type and its effect on liver function and blood lipid levels. Methods: A total of 140 cases of MAFLD patients with internal retention of dampness turbidity type were divided into the control group and the observation group according to the random number table method,70 cases in each group. The control group was treated with silybin combined with reasonable diet, appropriate exercise, and control of body weight; the observation group was additionally treated with Baogan Jiangzhi prescription based on the treatment of the control group. Both groups were treated for three months. Before and after treatment,the Chinese medicine syndrome scores,liver function indexes and blood lipid levels in the two groups were compared. The clinical effect in the two groups was compared. Results: After treatment, the Chinese medicine syndrome scores in the two groups were decreased when compared with those before treatment(P<0.05), and the score in the observation group was lower than that in the control group(P<0.05). The total effective rate was 92.86% in the observation group, higher than that of 80.00% in the control group(P<0.05). After treatment,the levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST) and γ-glutamyl transferase(GGT) in serum in the two groups were decreased when compared with those before treatment(P<0.05), and the above levels in serum in the observation group were lower than those in the control group(P<0.05). After treatment, the levels of total cholesterol(TC), triglyceride(TG) and low density lipoprotein cholesterol(LDL- C) in the two groups were decreased when compared with those before treatment(P<0.05),high density lipoprotein cholesterol(HDL-C) levels were increased(P<0.05); the levels of TC, TG and LDL- C in the observation group were lower than those in the control group(P<0.05), and the HDL- C level was higher(P<0.05). Conclusion: Baogan Jiangzhi prescription combined with silybin for MAFLD of internal retention of dampness turbidity type can improve clinical symptoms,liver function and blood lipid levels of patients.

    参考文献
    相似文献
    引证文献
引用本文

叶小丹,陈剑,朱小区.保肝降脂方联合水飞蓟宾治疗湿浊内停型代谢相关脂肪性肝病临床研究[J].新中医,2021,53(9):43-45

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-05-12
  • 出版日期:
文章二维码